See every side of every news story
Published loading...Updated

Mucosal Unadjuvanted Booster Vaccines Elicit Local IgA Responses by Conversion of Pre-Existing Immunity in Mice

  • A nasal vaccine could be more effective and tolerable for children and adults afraid of needles.
  • Participants who received the highest dose of CVXGA showed significantly lower rates of symptomatic COVID-19 infection.
  • The vaccine produced a mucosal antibody response rate of 51.9% in higher dose groups, compared to 21.4% in lower dose groups.
  • Based on phase 1 trial data, two larger clinical studies are currently underway.
Insights by Ground AI
Does this summary seem wrong?

31 Articles

Rutland HeraldRutland Herald
+27 Reposted by 27 other sources
Center

Nasal COVID Vax Shows Promise in Phase 1 Clinical Trial

CINCINNATI, July 4, 2025 /PRNewswire/ -- During the COVID-19 pandemic, scientists learned that the critical path to infection started with the SARS-CoV-2 virus invading the nasal tissues of its victims, then causing millions of deaths by spreading through the body…

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 59% of the sources are Center
59% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States on Friday, July 4, 2025.
Sources are mostly out of (0)